EGFR and lung cancer: The presence of the mutated epidermal growth factor receptor (EGFR) alleles in exoDNA, especially mutations such as exon 19 Del and exon 21 L858R, characteristic of lung cancer cells, may be important when selecting patients for targeted therapy using a tyrosine kinase inhibitor [40, 47].